| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5697919 | Clinical Oncology | 2016 | 12 Pages |
Abstract
The analysis of data showed that CTLA-4 inhibitors seem to be associated with a higher risk of all- and high-grade fatigue compared with control regimens, whereas PD-1 inhibitors seem to be associated with a lower risk of all- and high-grade fatigue compared with control regimens.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
O. Abdel-Rahman, D. Helbling, J. Schmidt, U. Petrausch, A. Giryes, A. Mehrabi, O. Schöb, M. Mannhart, A. Zidan, H. Oweira,